Liana B. Guedes
YOU?
Author Swipe
View article: Supplementary Table S4 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supplementary Table S4 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
Demographic and clinical-pathologic characteristics of eligible patients in intermediate/high risk radical prostatectomy cohort
View article: Supp Fig S4 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S4 from MSH2 Loss in Primary Prostate Cancer Open
MSH2/6 immunostains in a formalin fixed and paraffin embedded primary prostate tumor with single copy MSH2 loss by sequencing. Standard tissue section of tumor with apparent single copy somatic gene inactivation of MSH2 (MSH2 c. 1728del), …
View article: Data from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Data from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Purpose: RNA expression of androgen receptor splice variants may be a biomarker of resistance to novel androgen deprivation therapies in castrate-resistant prostate cancer (CRPC). We analytically validated an RNA in situ hybr…
View article: Supplementary Table S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Supplementary Table S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
RNA-seq reads spanning selected AR junctions in the RNA-seq data of CRPC samples from GSE50630, which was depleted of ribosomal RNA but not enriched for polyA transcripts
View article: 'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
'Representative examples of primary tumors with discordant TP53 sequencing and p53 immunostaining results on tissue microarray. Two tumors with TP53 missense mutations (upper left and upper right) did not show appreciable nuclear accumulat…
View article: Supplementary Figure S5 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Supplementary Figure S5 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Correlation of AR protein by IHC and AR-E1 RISH labeling in high grade primary tumors and benign prostate epithelium sampled on needle biopsy (Figure 5). (A) AR IHC quantified as brown/(brown+blue) pixels vs AR-E1 quantification shows a we…
View article: Data from MSH2 Loss in Primary Prostate Cancer
Data from MSH2 Loss in Primary Prostate Cancer Open
Purpose: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects.Experimental Design: A total of 1,133 primary p…
View article: Data from <i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
Data from <i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer Open
Purpose:The potential biological determinants of aggressive prostate cancer in African American (AA) men are unknown. Here we characterize prostate cancer genomic alterations in the largest cohort to date of AA men with clinical follow-up …
View article: Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer Open
PD-L1 immunostaining in tumors with MSH2 loss. Standard tissue sections of tumors with MSH2 protein loss shows PD-L1 immunolabeling in lymphocytes predominantly (22966), in lymphocytes and focally in tumor cells (61879) and in lymphocytes …
View article: Data from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Data from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Purpose: RNA expression of androgen receptor splice variants may be a biomarker of resistance to novel androgen deprivation therapies in castrate-resistant prostate cancer (CRPC). We analytically validated an RNA in situ hybr…
View article: Supplementary Figure S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Supplementary Figure S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Supplementary Figure S1: AR-E1 and AR-CE3 RISH assays are specific. (A) AR-E1 is undetectable in AR-negative, untransfected M12 cells. Transfection with AR-FL construct is detectable by AR_E1, but not by AR_CE3 RISH as expected in M12 cell…
View article: Supplementary Data from <i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
Supplementary Data from <i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer Open
Supplementary Figure S1
View article: Supplementary Figure S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Supplementary Figure S1 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Supplementary Figure S1: AR-E1 and AR-CE3 RISH assays are specific. (A) AR-E1 is undetectable in AR-negative, untransfected M12 cells. Transfection with AR-FL construct is detectable by AR_E1, but not by AR_CE3 RISH as expected in M12 cell…
View article: Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
TP53 mutations in formalin fixed paraffin embedded cell lines stratified by immunohistochemistry (IHC) result. Bolded results indicate discordant samples.
View article: Data from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Data from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missen…
View article: Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer Open
Validation of MSH2 immunohistochemistry in formalin fixed paraffin embedded prostate cell lines and tumor tissue controls.
View article: Supp Fig S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supp Fig S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
p53 immunohistochemistry in radical prostatectomy sample detects p.R282W mutation. Note that this mutations was missed in a separate, poorly preserved tumor sample (see Supp Fig S1). Reduced from 200x magnification.
View article: supplemental legend from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
supplemental legend from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
supplemental legend
View article: Supp Tables from MSH2 Loss in Primary Prostate Cancer
Supp Tables from MSH2 Loss in Primary Prostate Cancer Open
Supplementary Tables
View article: Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer Open
Validation of MSH2 immunohistochemistry in formalin fixed paraffin embedded prostate cell lines and tumor tissue controls.
View article: Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer Open
PD-L1 immunostaining in tumors with MSH2 loss. Standard tissue sections of tumors with MSH2 protein loss shows PD-L1 immunolabeling in lymphocytes predominantly (22966), in lymphocytes and focally in tumor cells (61879) and in lymphocytes …
View article: Data from MSH2 Loss in Primary Prostate Cancer
Data from MSH2 Loss in Primary Prostate Cancer Open
Purpose: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects.Experimental Design: A total of 1,133 primary p…
View article: 'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
'Representative examples of primary tumors with discordant TP53 sequencing and p53 immunostaining results on tissue microarray. Two tumors with TP53 missense mutations (upper left and upper right) did not show appreciable nuclear accumulat…
View article: Supplementary Figure S3 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Supplementary Figure S3 from Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Open
Correlation of relative quantified AR-E1 and AR-CE3 RISH labeling with one another and with relative AR-FL and AR-V7 expression by RT-PCR in metastases from Figure 3. AR-E1 by RISH and AR-V7 by RT-PCR are significantly correlated (A), as a…
View article: Supplementary Table S4 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supplementary Table S4 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
Demographic and clinical-pathologic characteristics of eligible patients in intermediate/high risk radical prostatectomy cohort
View article: Supp Fig S3 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S3 from MSH2 Loss in Primary Prostate Cancer Open
Additional immunostains of the mismatch repair proteins in a formalin fixed and paraffin embedded primary prostate tumor with germline and somatic MSH2 loss from Figure 1. The tumor has bi-allelic inactivation of MSH2 and shows complete lo…
View article: Data from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Data from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missen…
View article: Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
TP53 mutations in formalin fixed paraffin embedded cell lines stratified by immunohistochemistry (IHC) result. Bolded results indicate discordant samples.
View article: Supplementary Table S1 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supplementary Table S1 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
Tissue cohorts included in the study
View article: Supp Fig S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer
Supp Fig S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer Open
p53 immunohistochemistry in radical prostatectomy sample detects p.R282W mutation. Note that this mutations was missed in a separate, poorly preserved tumor sample (see Supp Fig S1). Reduced from 200x magnification.